Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints
Summary: Autoimmune hepatitis (AIH) is a rare chronic liver disease with an increasing incidence in many countries. Chronic autoimmune responses against the liver can cause hepatic and extrahepatic symptoms, decreased quality of life and reduced liver transplant-free survival if inadequately treated...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924002696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206882103459840 |
|---|---|
| author | Bastian Engel David N. Assis Mamatha Bhat Jan Clusmann Joost PH. Drenth Alessio Gerussi María-Carlota Londoño Ye Htun Oo Ida Schregel Marcial Sebode Richard Taubert |
| author_facet | Bastian Engel David N. Assis Mamatha Bhat Jan Clusmann Joost PH. Drenth Alessio Gerussi María-Carlota Londoño Ye Htun Oo Ida Schregel Marcial Sebode Richard Taubert |
| author_sort | Bastian Engel |
| collection | DOAJ |
| description | Summary: Autoimmune hepatitis (AIH) is a rare chronic liver disease with an increasing incidence in many countries. Chronic autoimmune responses against the liver can cause hepatic and extrahepatic symptoms, decreased quality of life and reduced liver transplant-free survival if inadequately treated. Although standard treatment with corticosteroids and thiopurines improves the life expectancy of patients with AIH, remission rates and tolerability are generally overestimated and the development of alternative first-line and salvage therapies has been disappointingly slow compared to in rheumatological diseases or inflammatory bowel disease. Other gaps include the lack of disease-specific diagnostic markers for AIH. Similarly, the new entity of drug-induced autoimmune-like hepatitis underscores the need to re-evaluate previous diagnostic criteria. The International AIH Group (IAIHG) has initiated a series of research workshops over the last decade to promote the identification of research gaps and subsequently improve the pace of scientific progress by stimulating collaboration between expert centres. This review reports on the results of the 5th Research Workshop, held in Hannover, Germany in June 2024, and summarises the progress made since the 4th Workshop in 2022. Patient representatives from the European Reference Network (ERN) Rare Liver Youth Panel participated in the workshop. The specific objectives of this year's 5th Workshop were: (1) To further improve diagnostics. (2) Initiate clinical trials including knowledge transfer on drugs from extrahepatic immune-mediated diseases, including B cell-depleting CAR T cells. (3) Utilisation of multi-omics approaches to improve the understanding of disease pathogenesis. (4) Application of machine learning-based approaches established in oncology or transplantation medicine to improve diagnosis and outcome prediction in AIH. |
| format | Article |
| id | doaj-art-85f3a71c58464d90b1d70e75a2aad0c3 |
| institution | Kabale University |
| issn | 2589-5559 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj-art-85f3a71c58464d90b1d70e75a2aad0c32025-02-07T04:48:09ZengElsevierJHEP Reports2589-55592025-02-0172101265Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024KeypointsBastian Engel0David N. Assis1Mamatha Bhat2Jan Clusmann3Joost PH. Drenth4Alessio Gerussi5María-Carlota Londoño6Ye Htun Oo7Ida Schregel8Marcial Sebode9Richard Taubert10Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; Corresponding author. Address: Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.Yale School of Medicine, New Haven, CT USAAjmera Transplant Centre, University Health Network, Toronto, Ontario, CanadaElse Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany; Department of Medicine III, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, The NetherlandsDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Centre for Autoimmune Liver Diseases & Division of Gastroenterology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ItalyLiver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Universitat de Barcelona, Centro de investigación biomédica en red Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, SpainLiver Transplant and Hepatobiliary Unit, Queen Elizabeth Hospital, University Hospital of Birmingham NHS Foundation Trust & Centre for Liver and Gastro Research, NIHR Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKI. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, GermanyI. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, GermanyDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; Corresponding author. Address: Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.Summary: Autoimmune hepatitis (AIH) is a rare chronic liver disease with an increasing incidence in many countries. Chronic autoimmune responses against the liver can cause hepatic and extrahepatic symptoms, decreased quality of life and reduced liver transplant-free survival if inadequately treated. Although standard treatment with corticosteroids and thiopurines improves the life expectancy of patients with AIH, remission rates and tolerability are generally overestimated and the development of alternative first-line and salvage therapies has been disappointingly slow compared to in rheumatological diseases or inflammatory bowel disease. Other gaps include the lack of disease-specific diagnostic markers for AIH. Similarly, the new entity of drug-induced autoimmune-like hepatitis underscores the need to re-evaluate previous diagnostic criteria. The International AIH Group (IAIHG) has initiated a series of research workshops over the last decade to promote the identification of research gaps and subsequently improve the pace of scientific progress by stimulating collaboration between expert centres. This review reports on the results of the 5th Research Workshop, held in Hannover, Germany in June 2024, and summarises the progress made since the 4th Workshop in 2022. Patient representatives from the European Reference Network (ERN) Rare Liver Youth Panel participated in the workshop. The specific objectives of this year's 5th Workshop were: (1) To further improve diagnostics. (2) Initiate clinical trials including knowledge transfer on drugs from extrahepatic immune-mediated diseases, including B cell-depleting CAR T cells. (3) Utilisation of multi-omics approaches to improve the understanding of disease pathogenesis. (4) Application of machine learning-based approaches established in oncology or transplantation medicine to improve diagnosis and outcome prediction in AIH.http://www.sciencedirect.com/science/article/pii/S2589555924002696rheumatologychimeric antigen receptorartificial intelligence |
| spellingShingle | Bastian Engel David N. Assis Mamatha Bhat Jan Clusmann Joost PH. Drenth Alessio Gerussi María-Carlota Londoño Ye Htun Oo Ida Schregel Marcial Sebode Richard Taubert Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints JHEP Reports rheumatology chimeric antigen receptor artificial intelligence |
| title | Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints |
| title_full | Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints |
| title_fullStr | Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints |
| title_full_unstemmed | Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints |
| title_short | Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints |
| title_sort | quo vadis autoimmune hepatitis summary of the 5th international autoimmune hepatitis group research workshop 2024keypoints |
| topic | rheumatology chimeric antigen receptor artificial intelligence |
| url | http://www.sciencedirect.com/science/article/pii/S2589555924002696 |
| work_keys_str_mv | AT bastianengel quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT davidnassis quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT mamathabhat quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT janclusmann quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT joostphdrenth quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT alessiogerussi quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT mariacarlotalondono quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT yehtunoo quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT idaschregel quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT marcialsebode quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints AT richardtaubert quovadisautoimmunehepatitissummaryofthe5thinternationalautoimmunehepatitisgroupresearchworkshop2024keypoints |